Options for the Treatment of Gemcitabine-Resistant Advanced Pancreatic Cancer: Are We There Yet?
Abstract
No abstract available.
Image: Yale Cancer Center. New Haven, CT, USA.
Downloads
References
Gounaris I, Zaki K, Corrie P. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer. JOP. J Pancreas (Online) 2010; 11:113-23. [PMID 20208317] (FULLTEXT: http://www.joplink.net/prev/201003/09.html)
Kang SP, Saif MW. Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP. J Pancreas (Online) 2008; 9:83-90. [PMID 18326918] (FULLTEXT: http://www.joplink.net/prev/200803/02.html)
Li J, Merl MY, Saif MW. Any second-line therapy for advanced pancreatic cancer? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP. J Pancreas (Online) 2010; 11:151-3. [PMID 20208325] (FULLTEXT: http://www.joplink.net/prev/201003/14.html)
Strimpakos AS, Syrigos KN, Saif MW. Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP. J Pancreas (Online) 2009; 10:357-60. [PMID 19581734] (FULLTEXT: http://www.joplink.net/prev/200907/26.html)
Novarino A, Satolli MA, Chiappino I, Giacobino A, Bellone G, Rahimi F, et al. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Am J Clin Oncol 2009; 32:44-8. [PMID 19194124] (FULLTEXT: http://journals.lww.com/amjclinicaloncology/Abstract/2009/02000/Oxaliplatin,_5_Fluorouracil,_and_Leucovorin_as.10.aspx)
Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 2005; 23:369-75. [PMID 16012797] (FULLTEXT: http://www.springerlink.com/content/q9125u415347r742/fulltext.pdf)
Hwang J, Yoo C, Kim T, Lee J, Park D, Seo D, et al. A randomised phase II trial of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy. J Clin Oncol 2009; 27(15 Suppl.):4618. (FULLTEXT: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4618)
Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113:2046-52. [PMID 18756532] (FULLTEXT: http://www3.interscience.wiley.com/cgi-bin/fulltext/121391199/HTMLSTART)
Sancho A, Lopez-Vivanco G, Diaz de Corcuera I, Ferreiro J, Moreno A, Mielgo X, et al. Oxaliplatin and capecitabine after gemcitabine failure in patients with advanced pancreatic, biliary or gallbladder adenocarcinoma (APBC). J Clin Oncol 2008; 26:s15625. (FULLTEXT: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/15625)
Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94:481-5. [PMID 16434988] (FULLTEXT: http://www.nature.com/bjc/journal/v94/n4/full/6602966a.html)
Dakik HK, Moskovic DJ, Carlson PJ, Qiao W, Ho L, Tamm E, et al. Evaluation of gemcitabine, docetaxel, capecitabine (GTX) in previously treated pancreatic cancer. ASCO Gastrointestinal Cancers Symposium 2010. Abstract No. 221.
Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 2007; 73:221-7. [PMID 18424886] (FULLTEXT: http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowFulltext&ArtikelNr=000127413&Ausgabe=236918&ProduktNr=223857)
Saif MW, Li J, Lamb L, Rosenberg A, Elligers K, Ruta S, et al. A phase II study of capecitabine (CAP) plus PHY906 in patients (pts) with advanced pancreatic cancer (APC). J Clin Oncol 2009; 27(15 Suppl.):e15508. (FULLTEXT: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e15508)
Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, et al. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 2009; 63:1141-5. [PMID 18839175] (FULLTEXT: http://www.springerlink.com/content/0q3p416g83003058/fulltext.html)
Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007; 25:4787-92. [PMID 17947726] (FULLTEXT: http://jco.ascopubs.org/cgi/reprint/25/30/4787.pdf)
Cereda S, Reni M. Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemother 2008; 20:509-12. [PMID 18676234] (FULLTEXT: http://www.jchemother.it/cgi-bin/digisuite.exe/product?ID=1806&IDCategory=141)
Tang P, Gill S, Au HJ, Chen EX, Hedley D, Leroux M, et al. Phase II trial of erlotinib in advanced pancreatic cancer (PC). J Clin Oncol 2009; 27(15 Suppl.):4609. (FULLTEXT: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4609)
Copyright (c) 2010 Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.